Literature DB >> 32165133

Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis.

Noah A Schuster1, Emiel O Hoogendijk2, Almar A L Kok3, Jos W R Twisk2, Martijn W Heymans2.   

Abstract

OBJECTIVE: Competing events are often ignored in epidemiological studies. Conventional methods for the analysis of survival data assume independent or noninformative censoring, which is violated when subjects that experience a competing event are censored. Because many survival studies do not apply competing risk analysis, we explain and illustrate in a nonmathematical way how to analyze and interpret survival data in the presence of competing events. STUDY DESIGN AND
SETTING: Using data from the Longitudinal Aging Study Amsterdam, both marginal analyses (Kaplan-Meier method and Cox proportional-hazards regression) and competing risk analyses (cumulative incidence function [CIF], cause-specific and subdistribution hazard regression) were performed. We analyzed the association between sex and depressive symptoms, in which death before the onset of depression was a competing event.
RESULTS: The Kaplan-Meier method overestimated the cumulative incidence of depressive symptoms. Instead, the CIF should be used. As the subdistribution hazard model has a one-to-one relation with the CIF, it is recommended for prediction research, whereas the cause-specific hazard model is recommended for etiologic research.
CONCLUSION: When competing risks are present, the type of research question guides the choice of the analytical model to be used. In any case, results should be presented for all event types.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Censoring; Competing risk analysis; Cumulative incidence; Epidemiological methods; Hazard; Survival analysis

Year:  2020        PMID: 32165133     DOI: 10.1016/j.jclinepi.2020.03.004

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  25 in total

1.  Implementation of an Alternative Method for Assessing Competing Risks: Restricted Mean Time Lost.

Authors:  Hongji Wu; Hao Yuan; Zijing Yang; Yawen Hou; Zheng Chen
Journal:  Am J Epidemiol       Date:  2022-01-01       Impact factor: 5.363

2.  Increased risk of metastasis in patients with incidental use of renin-angiotensin system inhibitors: a retrospective analysis for multiple types of cancer based on electronic medical records.

Authors:  Akie Hirata; Shin Ishikane; Fumi Takahashi-Yanaga; Masaki Arioka; Tasuku Okui; Chinatsu Nojiri; Toshiyuki Sasaguri; Naoki Nakashima
Journal:  Hypertens Res       Date:  2022-09-28       Impact factor: 5.528

3.  Pre-eclampsia is associated with increased neurodevelopmental disorders in children with congenital heart disease.

Authors:  Camilla Omann; Camilla Nyboe; Rasmus Kristensen; Andreas Ernst; Cecilia Høst Ramlau-Hansen; Charlotte Rask; Ann Tabor; J William Gaynor; Vibeke E Hjortdal
Journal:  Eur Heart J Open       Date:  2022-04-21

4.  Risk factors for graft loss and death among kidney transplant recipients: A competing risk analysis.

Authors:  Jessica Pinto-Ramirez; Andrea Garcia-Lopez; Sergio Salcedo-Herrera; Nasly Patino-Jaramillo; Juan Garcia-Lopez; Jefferson Barbosa-Salinas; Sergio Riveros-Enriquez; Gilma Hernandez-Herrera; Fernando Giron-Luque
Journal:  PLoS One       Date:  2022-07-14       Impact factor: 3.752

Review 5.  Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Authors:  Amir Razaghizad; Emily Oulousian; Varinder Kaur Randhawa; João Pedro Ferreira; James M Brophy; Stephen J Greene; Julian Guida; G Michael Felker; Marat Fudim; Michael Tsoukas; Tricia M Peters; Thomas A Mavrakanas; Nadia Giannetti; Justin Ezekowitz; Abhinav Sharma
Journal:  J Am Heart Assoc       Date:  2022-05-16       Impact factor: 6.106

6.  Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy.

Authors:  David F Moreno; Arturo Pereira; Natalia Tovar; María Teresa Cibeira; Laura Magnano; María Rozman; Mónica López-Guerra; Dolors Colomer; Beatriz Martín-Antonio; Raquel Jiménez-Segura; Ignacio Isola; Luis Gerardo Rodríguez-Lobato; Aina Oliver-Caldés; Mari Pau Mena; Laura Rosiñol; Joan Bladé; Carlos Fernández de Larrea
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

7.  Research on Brand Illustration Innovative Design Modeling Based on Industry 4.0.

Authors:  Yueyan Liu; Zou Ping
Journal:  Comput Intell Neurosci       Date:  2022-04-11

8.  Kidney Transplants in Controlled Donation Following Circulatory Death, or Maastricht Type III Donors, With Abdominal Normothermic Regional Perfusion, Optimizing Functional Outcomes.

Authors:  Patricia Ramirez; David Vázquez; Gabriel Rodríguez; Juan José Rubio; Marina Pérez; Jose Maria Portolés; Joaquín Carballido
Journal:  Transplant Direct       Date:  2021-07-16

9.  Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma.

Authors:  James G Connolly; Kay See Tan; Brooke Mastrogiacomo; Joseph Dycoco; Raul Caso; Gregory D Jones; Patrick J McCormick; Francisco Sanchez-Vega; Takeshi Irie; Joseph R Scarpa; Hersh V Gupta; Prasad S Adusumilli; Gaetano Rocco; James M Isbell; Matthew J Bott; Gregory W Fischer; David R Jones; Joshua S Mincer
Journal:  Br J Anaesth       Date:  2021-07       Impact factor: 11.719

10.  Estimating the potential for dementia prevention through modifiable risk factors elimination in the real-world setting: a population-based study.

Authors:  Elena Rolandi; Daniele Zaccaria; Roberta Vaccaro; Simona Abbondanza; Laura Pettinato; Annalisa Davin; Antonio Guaita
Journal:  Alzheimers Res Ther       Date:  2020-08-07       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.